NOM1 Inhibitors
NOM1 inhibitors encompass a variety of chemical compounds designed to interfere with the signaling pathways and biological processes that are essential for the proper functioning of NOM1. For instance, Staurosporine and Imatinib are kinase inhibitors that obstruct critical phosphorylation steps required for NOM1 activity. Staurosporine, being a broad-spectrum inhibitor, may suppress phosphorylation events essential for NOM1 activation, while Imatinib's selective inhibition of certain tyrosine kinases can reduce NOM1 activity if NOM1 modulation involves these kinases. Similarly, PI3K pathway inhibitors like LY294002 and Wortmannin are pertinent as they can diminish NOM1 activity through the inhibition of downstream targets, assuming NOM1 is regulated by this pathway. Sorafenib's inhibition of the Ras/Raf/MEK/ERK pathway presents another potential mechanism to reduce NOM1 activity by disrupting a cascade that may involve NOM1.
The inhibitory scope extends to modulators of the MAPK pathway, such as U0126 and PD98059, which prevent activation of ERK, indirectly affecting NOM1's regulatory mechanisms within this pathway. SB203580 and SP600125 target p38 MAPK and JNK, respectively, both of which could be crucial for NOM1 activation or stabilization, particularlyif NOM1 is implicated in cellular stress responses or apoptosis. Rapamycin's targeting of mTOR, a central regulator of cell growth, may also impede NOM1 activity, especially if NOM1 is associated with mTOR-regulated pathways. Further, Dasatinib and PP2 focus on Src family kinases and BCR-ABL, potentially diminishing NOM1 activity through the inhibition of signaling networks where these kinases govern regulatory nodes that may affect NOM1 function. Collectively, these inhibitors operate by disrupting specific kinase activities, signaling pathways, and regulatory mechanisms that are vital for NOM1's role in cellular processes, thereby achieving a decrease in NOM1 functional activity without affecting its transcription or translation.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent, broad-spectrum inhibitor of protein kinases. By inhibiting protein kinases, it can suppress the phosphorylation events necessary for the activation of NOM1, thereby reducing its functional activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that impedes the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. Inhibition of this pathway can result in decreased phosphorylation and activation of various downstream targets, potentially including NOM1, if it is regulated by the PI3K/Akt pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. By inhibiting p38 MAPK, it disrupts the MAPK signaling pathway which could be crucial for the activation or stabilization of NOM1. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are upstream of ERK in the MAPK pathway. By preventing ERK activation, U0126 could indirectly affect the NOM1 function if it is regulated by the ERK pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor, which, like LY294002, would reduce NOM1 activity by inhibiting the PI3K/Akt signaling pathway assuming NOM1 is a downstream target. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that blocks the activation of ERK, which is part of the MAPK pathway. This inhibition can indirectly reduce the activity of NOM1 by affecting its regulatory mechanisms within the MAPK pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which is a key regulator of cell growth and proliferation. By inhibiting mTOR, Rapamycin may decrease NOM1 activity if NOM1 is involved in pathways regulated by mTOR. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of the c-Jun N-terminal kinase (JNK), which plays a role in stress-induced apoptosis. Inhibiting JNK can affect NOM1 if it is involved in apoptosis or other cellular stress responses regulated by JNK. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib selectively inhibits certain tyrosine kinases, which could lead to a reduction in NOM1 activity if NOM1 is modulated by any of these tyrosine kinases or their signaling cascades. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib targets multiple kinases, including those in the Ras/Raf/MEK/ERK pathway. By inhibiting this pathway, Sorafenib could indirectly reduce NOM1 activity if NOM1 is associated with this signaling cascade. | ||||||